Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen highlights oncology pipeline data

Amgen highlights oncology pipeline data

4th April 2008

Amgen has announced that results from a number of clinical and preclinical trials investigating cancer treatment will be presented at the American Association for Cancer Research annual meeting later this month.

Data on pipeline compounds AMG 102, AMG 386, AMG 479, AMG 655 and AMG 706 will be presented by the firm at the event, which is set to take place between April 12th and 16th.

Early studies have offered the firm the biological evidence to allow Amgen to launch new exploratory programmes with the five molecules.

“These data underscore our ongoing exploration of key biological processes that influence the growth of cancer cells including angiogenesis, apoptosis and growth regulation,” said Dr David Chang, the vice-president of global oncology development at the firm.

In related news, the firm is partnering with the National Kidney Foundation to track patients in a bid to address the issue of chronic kidney disease.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.